Product NDC: | 0173-0822 |
Proprietary Name: | Staxyn |
Non Proprietary Name: | vardenafil hydrochloride |
Active Ingredient(s): | 11.85 mg/1 & nbsp; vardenafil hydrochloride |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, ORALLY DISINTEGRATING |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0173-0822 |
Labeler Name: | GlaxoSmithKline LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA200179 |
Marketing Category: | NDA |
Start Marketing Date: | 20110421 |
Package NDC: | 0173-0822-61 |
Package Description: | 1 BLISTER PACK in 1 BOX (0173-0822-61) > 2 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK |
NDC Code | 0173-0822-61 |
Proprietary Name | Staxyn |
Package Description | 1 BLISTER PACK in 1 BOX (0173-0822-61) > 2 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK |
Product NDC | 0173-0822 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | vardenafil hydrochloride |
Dosage Form Name | TABLET, ORALLY DISINTEGRATING |
Route Name | ORAL |
Start Marketing Date | 20110421 |
Marketing Category Name | NDA |
Labeler Name | GlaxoSmithKline LLC |
Substance Name | VARDENAFIL HYDROCHLORIDE TRIHYDRATE |
Strength Number | 11.85 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Phosphodiesterase 5 Inhibitor [EPC],Phosphodiesterase 5 Inhibitors [MoA] |